Annual EBITDA
-$67.83 M
+$153.74 M+69.39%
December 31, 2023
Summary
- As of February 24, 2025, ACAD annual EBITDA is -$67.83 million, with the most recent change of +$153.74 million (+69.39%) on December 31, 2023.
- During the last 3 years, ACAD annual EBITDA has risen by +$215.83 million (+76.09%).
- ACAD annual EBITDA is now -531.99% below its all-time high of $15.70 million, reached on December 31, 2010.
Performance
ACAD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$34.21 M
+$1.21 M+3.65%
September 30, 2024
Summary
- As of February 24, 2025, ACAD quarterly EBITDA is $34.21 million, with the most recent change of +$1.21 million (+3.65%) on September 30, 2024.
- Over the past year, ACAD quarterly EBITDA has increased by +$90.27 million (+161.04%).
- ACAD quarterly EBITDA is now -6.47% below its all-time high of $36.58 million, reached on December 31, 2023.
Performance
ACAD Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$124.54 M
+$90.27 M+263.37%
September 30, 2024
Summary
- As of February 24, 2025, ACAD TTM EBITDA is $124.54 million, with the most recent change of +$90.27 million (+263.37%) on September 30, 2024.
- Over the past year, ACAD TTM EBITDA has increased by +$274.52 million (+183.04%).
- ACAD TTM EBITDA is now at all-time high.
Performance
ACAD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ACAD EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +69.4% | +161.0% | +183.0% |
| 3 y3 years | +76.1% | +339.0% | +165.8% |
| 5 y5 years | +72.3% | +176.4% | +151.1% |
ACAD EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +69.4% | -6.5% | +130.4% | at high | +156.2% |
| 5 y | 5-year | at high | +76.1% | -6.5% | +130.4% | at high | +143.9% |
| alltime | all time | -532.0% | +76.6% | -6.5% | +130.4% | at high | +140.3% |
ACADIA Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $34.21 M(+3.7%) | $124.54 M(+263.4%) |
| Jun 2024 | - | $33.01 M(+59.2%) | $34.27 M(+464.7%) |
| Mar 2024 | - | $20.74 M(-43.3%) | $6.07 M(-108.9%) |
| Dec 2023 | -$67.83 M(-69.4%) | $36.58 M(-165.3%) | -$67.83 M(-54.8%) |
| Sep 2023 | - | -$56.05 M(-1267.0%) | -$149.98 M(+20.7%) |
| Jun 2023 | - | $4.80 M(-109.0%) | -$124.29 M(-23.4%) |
| Mar 2023 | - | -$53.16 M(+16.6%) | -$162.23 M(-26.8%) |
| Dec 2022 | -$221.57 M(+32.6%) | -$45.57 M(+50.1%) | -$221.57 M(+0.7%) |
| Sep 2022 | - | -$30.36 M(-8.4%) | -$220.12 M(+7.9%) |
| Jun 2022 | - | -$33.14 M(-70.5%) | -$204.07 M(-4.5%) |
| Mar 2022 | - | -$112.50 M(+155.0%) | -$213.72 M(+27.9%) |
| Dec 2021 | -$167.09 M(-41.1%) | -$44.12 M(+208.2%) | -$167.09 M(-11.7%) |
| Sep 2021 | - | -$14.32 M(-66.5%) | -$189.30 M(-27.2%) |
| Jun 2021 | - | -$42.78 M(-35.1%) | -$260.17 M(-0.2%) |
| Mar 2021 | - | -$65.88 M(-0.7%) | -$260.68 M(-8.1%) |
| Dec 2020 | -$283.65 M(+16.4%) | -$66.32 M(-22.1%) | -$283.65 M(+3.9%) |
| Sep 2020 | - | -$85.19 M(+96.8%) | -$273.09 M(+17.4%) |
| Jun 2020 | - | -$43.29 M(-51.3%) | -$232.67 M(-5.3%) |
| Mar 2020 | - | -$88.85 M(+59.3%) | -$245.78 M(+0.8%) |
| Dec 2019 | -$243.78 M(-0.3%) | -$55.76 M(+24.6%) | -$243.78 M(-4.2%) |
| Sep 2019 | - | -$44.77 M(-20.6%) | -$254.51 M(-5.8%) |
| Jun 2019 | - | -$56.40 M(-35.1%) | -$270.26 M(-2.5%) |
| Mar 2019 | - | -$86.85 M(+30.6%) | -$277.23 M(+13.4%) |
| Dec 2018 | -$244.44 M(-15.6%) | -$66.49 M(+9.9%) | -$244.44 M(-1.1%) |
| Sep 2018 | - | -$60.52 M(-4.5%) | -$247.25 M(-1.8%) |
| Jun 2018 | - | -$63.37 M(+17.2%) | -$251.68 M(-1.6%) |
| Mar 2018 | - | -$54.06 M(-22.0%) | -$255.67 M(-11.7%) |
| Dec 2017 | -$289.70 M(+6.9%) | -$69.31 M(+6.7%) | -$289.70 M(-2.8%) |
| Sep 2017 | - | -$64.95 M(-3.6%) | -$297.99 M(-2.2%) |
| Jun 2017 | - | -$67.36 M(-23.5%) | -$304.83 M(-1.3%) |
| Mar 2017 | - | -$88.08 M(+13.5%) | -$308.94 M(+14.0%) |
| Dec 2016 | -$270.99 M(+65.3%) | -$77.60 M(+8.1%) | -$270.99 M(+13.5%) |
| Sep 2016 | - | -$71.79 M(+0.4%) | -$238.82 M(+16.0%) |
| Jun 2016 | - | -$71.47 M(+42.6%) | -$205.91 M(+18.6%) |
| Mar 2016 | - | -$50.12 M(+10.3%) | -$173.66 M(+5.9%) |
| Dec 2015 | -$163.97 M(+76.3%) | -$45.44 M(+16.9%) | -$163.97 M(+11.5%) |
| Sep 2015 | - | -$38.88 M(-0.9%) | -$147.02 M(+10.5%) |
| Jun 2015 | - | -$39.22 M(-3.0%) | -$133.07 M(+15.2%) |
| Mar 2015 | - | -$40.43 M(+41.9%) | -$115.54 M(+24.2%) |
| Dec 2014 | -$93.02 M(+143.4%) | -$28.49 M(+14.3%) | -$93.02 M(+21.4%) |
| Sep 2014 | - | -$24.93 M(+15.0%) | -$76.66 M(+22.6%) |
| Jun 2014 | - | -$21.68 M(+21.0%) | -$62.52 M(+25.1%) |
| Mar 2014 | - | -$17.91 M(+47.8%) | -$49.98 M(+30.8%) |
| Dec 2013 | -$38.22 M | -$12.13 M(+12.3%) | -$38.22 M(+16.2%) |
| Sep 2013 | - | -$10.79 M(+18.0%) | -$32.89 M(+34.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$9.14 M(+48.7%) | -$24.50 M(+17.9%) |
| Mar 2013 | - | -$6.15 M(-9.5%) | -$20.79 M(-0.4%) |
| Dec 2012 | -$20.78 M(-7.9%) | -$6.80 M(+182.4%) | -$20.86 M(+7.8%) |
| Sep 2012 | - | -$2.41 M(-55.7%) | -$19.35 M(-12.1%) |
| Jun 2012 | - | -$5.43 M(-12.9%) | -$22.01 M(-4.8%) |
| Mar 2012 | - | -$6.23 M(+17.9%) | -$23.13 M(+2.5%) |
| Dec 2011 | -$22.57 M(-243.7%) | -$5.28 M(+4.4%) | -$22.57 M(-287.4%) |
| Sep 2011 | - | -$5.06 M(-22.7%) | $12.04 M(-7.1%) |
| Jun 2011 | - | -$6.55 M(+15.4%) | $12.96 M(-15.6%) |
| Mar 2011 | - | -$5.67 M(-119.3%) | $15.35 M(-2.2%) |
| Dec 2010 | $15.70 M(-135.4%) | $29.32 M(-808.1%) | $15.70 M(-171.8%) |
| Sep 2010 | - | -$4.14 M(-0.4%) | -$21.88 M(-16.8%) |
| Jun 2010 | - | -$4.16 M(-21.9%) | -$26.30 M(-24.3%) |
| Mar 2010 | - | -$5.32 M(-35.6%) | -$34.74 M(-21.7%) |
| Dec 2009 | -$44.36 M(-32.7%) | -$8.26 M(-3.4%) | -$44.36 M(-11.8%) |
| Sep 2009 | - | -$8.55 M(-32.1%) | -$50.31 M(-11.8%) |
| Jun 2009 | - | -$12.60 M(-15.7%) | -$57.06 M(-9.4%) |
| Mar 2009 | - | -$14.94 M(+5.2%) | -$62.99 M(-5.0%) |
| Dec 2008 | -$65.94 M(+6.5%) | -$14.21 M(-7.2%) | -$66.33 M(-5.4%) |
| Sep 2008 | - | -$15.31 M(-17.4%) | -$70.08 M(-3.6%) |
| Jun 2008 | - | -$18.53 M(+1.4%) | -$72.66 M(+8.9%) |
| Mar 2008 | - | -$18.28 M(+1.8%) | -$66.73 M(+8.5%) |
| Dec 2007 | -$61.89 M(+26.2%) | -$17.96 M(+0.4%) | -$61.51 M(+7.7%) |
| Sep 2007 | - | -$17.89 M(+42.0%) | -$57.09 M(+10.8%) |
| Jun 2007 | - | -$12.60 M(-3.4%) | -$51.52 M(-0.1%) |
| Mar 2007 | - | -$13.05 M(-3.7%) | -$51.59 M(+6.5%) |
| Dec 2006 | -$49.05 M(+41.0%) | -$13.55 M(+10.0%) | -$48.45 M(+6.7%) |
| Sep 2006 | - | -$12.32 M(-2.8%) | -$45.39 M(-0.6%) |
| Jun 2006 | - | -$12.67 M(+27.8%) | -$45.67 M(+16.5%) |
| Mar 2006 | - | -$9.91 M(-5.5%) | -$39.20 M(+12.7%) |
| Dec 2005 | -$34.78 M(+40.3%) | -$10.49 M(-16.7%) | -$34.78 M(+10.8%) |
| Sep 2005 | - | -$12.59 M(+103.1%) | -$31.39 M(+26.5%) |
| Jun 2005 | - | -$6.20 M(+12.9%) | -$24.81 M(+2.6%) |
| Mar 2005 | - | -$5.49 M(-22.6%) | -$24.19 M(-2.4%) |
| Dec 2004 | -$24.79 M(+100.0%) | -$7.10 M(+18.0%) | -$24.79 M(-32.9%) |
| Sep 2004 | - | -$6.02 M(+7.9%) | -$36.97 M(+27.0%) |
| Jun 2004 | - | -$5.58 M(-8.5%) | -$29.10 M(+13.8%) |
| Mar 2004 | - | -$6.10 M(-68.4%) | -$25.57 M(+17.5%) |
| Dec 2003 | -$12.40 M(+10.5%) | -$19.27 M(-1144.9%) | -$21.75 M(+777.5%) |
| Sep 2003 | - | $1.84 M(-190.3%) | -$2.48 M(-42.7%) |
| Jun 2003 | - | -$2.04 M(-10.5%) | -$4.32 M(+89.5%) |
| Mar 2003 | - | -$2.28 M | -$2.28 M |
| Dec 2002 | -$11.22 M(-26.5%) | - | - |
| Dec 2001 | -$15.28 M(+35.6%) | - | - |
| Dec 2000 | -$11.27 M | - | - |
FAQ
- What is ACADIA Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for ACADIA Pharmaceuticals?
- What is ACADIA Pharmaceuticals annual EBITDA year-on-year change?
- What is ACADIA Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for ACADIA Pharmaceuticals?
- What is ACADIA Pharmaceuticals quarterly EBITDA year-on-year change?
- What is ACADIA Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for ACADIA Pharmaceuticals?
- What is ACADIA Pharmaceuticals TTM EBITDA year-on-year change?
What is ACADIA Pharmaceuticals annual EBITDA?
The current annual EBITDA of ACAD is -$67.83 M
What is the all time high annual EBITDA for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals all-time high annual EBITDA is $15.70 M
What is ACADIA Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ACAD annual EBITDA has changed by +$153.74 M (+69.39%)
What is ACADIA Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of ACAD is $34.21 M
What is the all time high quarterly EBITDA for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals all-time high quarterly EBITDA is $36.58 M
What is ACADIA Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ACAD quarterly EBITDA has changed by +$90.27 M (+161.04%)
What is ACADIA Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of ACAD is $124.54 M
What is the all time high TTM EBITDA for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals all-time high TTM EBITDA is $124.54 M
What is ACADIA Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ACAD TTM EBITDA has changed by +$274.52 M (+183.04%)